Thyroid Cancer (TC) Market View Report 2026: Ipsen/Exelixis, Ono Pharmaceutical, and Novartis Dominate the Treatment Landscape
Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Thyroid Cancer (TC): Market View" report has been added to ResearchAndMarkets.com's offering.
This reports provides a data-driven overview of the current and future competitive landscape in Thyroid Cancer Therapeutics.
Currently, approved targeted therapies have already become a part of the standard care for advanced thyroid cancer (with drugs selected based on the tumor's genetic profile), and immunotherapies are emerging as experimental options that might benefit certain patients. In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of thyroid cancer, representing a large portion of global cases.
The thyroid cancer pipeline holds 119 molecules, with no assets in the pre-registration stage, and eight assets in Phase III development. Over the past decade, 575 clinical trials have been conducted in thyroid cancer. The years with the most studies initiated were 2023 and 2022, with 66 trials, followed by 2021 with 62 trials.
During the past 22 months, 13 mergers and acquisitions and 18 strategic alliances involving companies developing thyroid cancer assets were completed globally. Ipsen/Exelixis, Ono Pharmaceutical, and Novartis dominate the thyroid cancer treatment landscape by marketing novel targeted therapies, and Novartis appears to retain its position with three targeted therapies in its late-stage pipeline.
Reasons to Buy
Components of the Report
Key Topics Covered:
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profile and Sales Forecast
5 Pricing and Reimbursement Assessment
6 Pipeline Drugs Assessment
6.1 Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Product Profile and Sales Forecast
6.6 Drug-specific PTSR and LoA
6.7 Indication-specific and Therapy Area-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Top 20 Biomarkers by Trial Phase
7.7 Overview of Trials by Geography
7.8 Single-Country and Multinational Trials by Region
7.9 Top 20 Sponsors with Breakdown by Phase
7.10 Top 20 Sponsors with Breakdown by Status
7.11 Overview by Endpoint Status
7.12 Overview by Race and Ethnicity
7.13 Enrollment Data
7.14 Top 20 countries for Trial Sites
7.15 Top 20 Sites Globally
7.16 Feasibility Analysis - Geographic Overview
7.17 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
11.1 Methodology
11.2 Methodology - Sales Forecast
11.3 Methodology - Pricing and Reimbursement
11.4 Methodology - PTSR and LoA Analysis
For more information about this report visit https://www.researchandmarkets.com/r/vnbkoe
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.